Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Intracranial Neoplasm
  • Low Grade Glioma
  • Recurrent Glioblastoma
  • Recurrent WHO Grade III Glioma
  • Recurrent World Health Organization (WHO) Grade II Glioma
Type
Interventional
Phase
Phase 2
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Diagnostic

Participation Requirements

Age
Between 3 years and 125 years
Gender
Both males and females

Description

PRIMARY OBJECTIVES: I. To determine if F-18 fluoroethyltyrosine (FET) PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology alone in population 1. II. To determine if FET PET can accurately differentiate between low-grade and high-grade glial neopla...

PRIMARY OBJECTIVES: I. To determine if F-18 fluoroethyltyrosine (FET) PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology alone in population 1. II. To determine if FET PET can accurately differentiate between low-grade and high-grade glial neoplasms in population 2. SECONDARY OBJECTIVES: I. To determine if FET PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology or imaging follow-up in population 1. II. To determine if FET PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology alone in population 1 patients with recurrent low-grade gliomas (grades 1 and 2). OUTLINE: Participants receive F-18 fluoroethyltyrosine intravenously (IV) over approximately 1 minute and undergo PET over 40 minutes. After completion of study treatment, participants are followed up periodically.

Tracking Information

NCT #
NCT04044937
Collaborators
Not Provided
Investigators
Principal Investigator: Thomas A Hope, MD University of California, San Francisco
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2024